Aptamer-modified gold nanoparticles for rapid aggregation-based detection of inflammation: an optical assay for interleukin-6

被引:0
作者
Susan Giorgi-Coll
María J. Marín
Olajumoke Sule
Peter J. Hutchinson
Keri L.H. Carpenter
机构
[1] University of Cambridge,Department of Clinical Neurosciences, Division of Neurosurgery
[2] University of East Anglia,School of Chemistry
[3] Cambridge University Hospitals NHS Trust,Clinical Microbiology and Public Health Laboratory
[4] University of Cambridge,Department of Clinical Neurosciences, Wolfson Brain Imaging Centre
来源
Microchimica Acta | 2020年 / 187卷
关键词
Cytokines; Colorimetry; Metal nanoparticles; Sepsis; Diagnostics; Point-of-care assay;
D O I
暂无
中图分类号
学科分类号
摘要
A proof-of-concept aptamer-based optical assay is described for the determination of the immuno signalling molecule interleukin-6 (IL-6), a key marker of acute inflammation. The optical assay is based on the aggregation of gold nanoparticles (AuNP) coated in two complimentary “sandwich-style” aptamers, each with different IL-6 target moieties. IL-6 will recognise the complimentary aptamer pair and bind to it, thereby causing the aggregation of the corresponding functionalised nanoparticles. The aggregation of the AuNPs after exposure to IL-6 induces a visible colour change from red to pink, with a corresponding change in the absorption maximum from 520 to 540 nm. The change in the absorption maximum can be monitored visually, or by using a spectrophotometer or a plate reader. The optimal size and functionalisation of aptamer-coated AuNPs, and the potential assay formats were investigated using UV-vis spectrophotometry, transmission electron microscopy, and dynamic light scattering. The optical assay was applied for detecting mouse IL-6 in a mixed protein solution as a representative biological sample. The assay works in the 3.3 to 125 μg·mL−1 IL-6 concentration range, and the detection limit (at S/N = 3) is 1.95 μg·mL−1. This study was performed as a proof-of-concept demonstration of this versatile assay design, with a view to developing a similar assay for use in clinical samples in future.
引用
收藏
相关论文
共 156 条
  • [1] Hunter CA(2015)IL-6 as a keystone cytokine in health and disease Nat Immunol 16 448-457
  • [2] Jones SA(2015)Chronic inflammation after severe traumatic brain injury: characterization and associations with outcome at 6 and 12 months postinjury J Head Trauma Rehabil 30 369-381
  • [3] Kumar RG(2016)Time course of cerebrospinal fluid inflammatory biomarkers and relationship to 6-month neurologic outcome in adult severe traumatic brain injury Clin Neurol Neurosurg 149 1-5
  • [4] Boles JA(2016)Elevated IL-6 and TNF-α levels in cerebrospinal fluid of subarachnoid hemorrhage patients Mol Neurobiol 53 3277-3285
  • [5] Wagner AK(2017)Interleukin 6 in the cerebrospinal fluid as a biomarker for onset of vasospasm and ventriculitis after severe subarachnoid hemorrhage World Neurosurg 99 132-139
  • [6] Nwachuku EL(2014)Usefulness of interleukin 6 levels in the cerebrospinal fluid for the diagnosis of bacterial meningitis J Crit Care 29 693.e1-693.e6
  • [7] Puccio AM(2014)Cerebrospinal fluid TNF-α, IL-6, and IL-8 in children with bacterial meningitis Pediatr Neurol 50 60-65
  • [8] Adeboye A(2014)Rapid diagnosis of sepsis Virulence 5 154-160
  • [9] Chang Y-F(2015)An early warning scoring system to identify septic patients in the prehospital setting: the PRESEP score Acad Emerg Med 22 868-871
  • [10] Kim J(2015)Interleukin-6 for diagnosis of sepsis in critically ill adult patients Cochrane Database Syst Rev 7 235-251